BACKGROUND AND OBJECTIVES: Increased bone resorption, low bone formation, and abnormal mineralization have been described in stone formers with idiopathic hypercalciuria. It has been previously shown that the receptor activator of NF-κB ligand mediates bone resorption in idiopathic hypercalciuria (IH). The present study aimed to determine the expression of fibroblast growth factor 23 (FGF-23), vitamin D receptor (VDR), and sclerostin in bone tissue from IH stone formers. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Immunohistochemical analysis was performed in undecalcified bone samples previously obtained for histomorphometry from 30 transiliac bone biopsies of idiopathic hypercalciuria stone-forming patients between 1992 and 2002 and 33 healthy individuals (controls). Serum parameters were obtained from their medical records. RESULTS: Histomorphometry disclosed 21 IH patients with high and 9 IH patients with normal bone resorption. Importantly, eroded surfaces (ES/BS) from IH patients but not controls were significantly correlated with VDR immunostaining in osteoblasts (r=0.51; P=0.004), sclerostin immunostaining in osteocytes (r=0.41; P=0.02), and serum 1,25-dihydroxyvitamin D (r=0.55; P<0.01). Of note, both VDR and sclerostin immunostaining were significantly correlated with serum 1,25-dihydroxyvitamin D in IH patients (r=0.52; P=0.01 and r=0.53; P=0.02, respectively), although VDR and sclerostin expression did not differ between IH and controls. IH patients with high bone resorption exhibited a significantly stronger sclerostin immunostaining than IH patients with normal bone resorption. FGF-23 expression in osteocytes from IH patients did not differ from controls and was not correlated with any histomorphometric parameter. CONCLUSIONS: These findings suggest the contribution of VDR and sclerostin, as well as 1,25-dihydroxyvitamin D, to increase bone resorption in idiopathic hypercalciuria but do not implicate FGF-23 in the bone alterations seen in these patients.
BACKGROUND AND OBJECTIVES: Increased bone resorption, low bone formation, and abnormal mineralization have been described in stone formers with idiopathic hypercalciuria. It has been previously shown that the receptor activator of NF-κB ligand mediates bone resorption in idiopathic hypercalciuria (IH). The present study aimed to determine the expression of fibroblast growth factor 23 (FGF-23), vitamin D receptor (VDR), and sclerostin in bone tissue from IH stone formers. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Immunohistochemical analysis was performed in undecalcified bone samples previously obtained for histomorphometry from 30 transiliac bone biopsies of idiopathic hypercalciuria stone-forming patients between 1992 and 2002 and 33 healthy individuals (controls). Serum parameters were obtained from their medical records. RESULTS: Histomorphometry disclosed 21 IHpatients with high and 9 IHpatients with normal bone resorption. Importantly, eroded surfaces (ES/BS) from IHpatients but not controls were significantly correlated with VDR immunostaining in osteoblasts (r=0.51; P=0.004), sclerostin immunostaining in osteocytes (r=0.41; P=0.02), and serum 1,25-dihydroxyvitamin D (r=0.55; P<0.01). Of note, both VDR and sclerostin immunostaining were significantly correlated with serum 1,25-dihydroxyvitamin D in IHpatients (r=0.52; P=0.01 and r=0.53; P=0.02, respectively), although VDR and sclerostin expression did not differ between IH and controls. IHpatients with high bone resorption exhibited a significantly stronger sclerostin immunostaining than IHpatients with normal bone resorption. FGF-23 expression in osteocytes from IHpatients did not differ from controls and was not correlated with any histomorphometric parameter. CONCLUSIONS: These findings suggest the contribution of VDR and sclerostin, as well as 1,25-dihydroxyvitamin D, to increase bone resorption in idiopathic hypercalciuria but do not implicate FGF-23 in the bone alterations seen in these patients.
Authors: A M Misael da Silva; L M dos Reis; R C Pereira; E Futata; C T Branco-Martins; I L Noronha; B L Wajchemberg; V Jorgetti Journal: Clin Nephrol Date: 2002-03 Impact factor: 0.975
Authors: L A Martini; L Cuppari; F A Colugnati; D M Sigulem; V L Szejnfeld; N Schor; I P Heilberg Journal: Clin Nephrol Date: 2000-08 Impact factor: 0.975
Authors: Calyani Ganesan; Benjamin Weia; I-Chun Thomas; Shen Song; Kyla Velaer; Carolyn D Seib; Simon Conti; Chris Elliott; Glenn M Chertow; Manjula Kurella Tamura; John T Leppert; Alan C Pao Journal: JAMA Surg Date: 2020-09-01 Impact factor: 16.681
Authors: Fernanda Guedes Rodrigues; Rodrigo Fernandes Carvalho Azambuja Neves; Milene Subtil Ormanji; Priscila Ligeiro Gonçalves Esper; Melissa Gaspar; Rosa Maria Rodrigues Pereira; Lucio R Requião-Moura; Martin H de Borst; Ita Pfeferman Heilberg Journal: J Pers Med Date: 2022-07-10
Authors: Maria Goretti Moreira Guimarães Penido; Marcelo de Sousa Tavares; Uri Saggie Alon Journal: Biomed Res Int Date: 2017-12-31 Impact factor: 3.411
Authors: Daniel A Wollin; Adam G Kaplan; Glenn M Preminger; Pietro Manuel Ferraro; Antonio Nouvenne; Andrea Tasca; Emanuele Croppi; Giovanni Gambaro; Ita P Heilberg Journal: Asian J Urol Date: 2018-06-26